Ever since its establishment in 1995, the European Medicines Agency (EMA) has been committed to transparency. That said, as of late the Agency has been criticized for lacking it. To address this criticism, the Agency is attempting to become even more transparent. In this commentary the author argues that the EMA is now moving almost too quickly toward complete transparency. Before launching a number of new transparency initiatives, it should consider arranging some workshops on the topic as well as pretesting its communication messages before they are put in the public domain.
European Medicines Agency. European Medicines Agency policy on access to documents (related to medicinal products for human and veterinary use). Policy: 0043. London, UK: European Medicines Agency; 2010.
2.
European Medicines Agency. The EMEA transparency draft for public consultation. London, UK: European Medicines Agency; 2009.
3.
European Medicines Agency. The European Medicines Agency Road Map to 2015: The Agency’s contribution to science, medicines, health. London, UK: European Medicines Agency; 2011.
4.
BarbuiCBaschirottoCCiprianiA.2011. EMA must improve the quality of its clinical trial reports. BMJ. 2001;342:d2291.
5.
GarattiniSBerteleV. How can we regulate medicines better?BMJ. 2007;335:803–805.
6.
GarattiniSBerteleV. Opening up data at the European Medicines Agency. BMJ. 2010;342:d2686.
7.
GotschePCJorgensenA. Opening up data at the European Medicines Agency. BMJ. 2011;342:d2686.
8.
HamptonT. European drug agency under fire. JAMA. 2011;306:593–595.
9.
European Medicines Agency—more transparency needed [editorial]. Lancet. 2010;375:1753.
10.
SmithR. Transparency: a modern essential. BMJ. 2004;328:1136.
11.
European Medicines Agency. European Medicines Agency sets out next steps on access to clinical-trial data. [press release]. London, UK: EMA; December 5, 2012.
12.
Heads of Medicines Agency/European Medicines Agency. HMA/EMA guidance document on the identification of commercially confidential information and personal data within the structure of the marketing authorization (MA) application-release of information after the granting of a marketing authorization. London, UK: European Medicines Agency; 2012.
13.
HamptonT. European drug agency works to improve transparency, but skepticism remains. JAMA. 2012;308:850–851.
14.
EichlerH-GAbadieEBreckenridgeALeufkensHRassiG.Open clinical trial for all? A view from the regulators. PloS Medicine. 2012;9(4):e1001202.
15.
GrimmelikhuijsenSG.Transparency of public decision-making: toward trust in local government?Policy and Internet. 2010;2(1):article 2.
